Clinical Trial Update: Safety and Tolerability Study of MCI-196 [Phase 3]

View source ↗

Summary

Phase 3 safety and tolerability study of MCI-196 in chronic kidney disease patients, including those not on dialysis and paediatric populations, has been termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• MCI-196

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Chronic Kidney Disease, Not on Dialysis | Phase 3 | Status: TERMINATED